{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["25(10)"],"submitter":["Gefen T"],"funding":["Sylvester Comprehensive Cancer Center, Medical School, University of Miami","Dodson Interdisciplinary Immunotherapy Institute"],"pubmed_abstract":["T cell immunoglobulin-3 (TIM-3) is a negative regulator of interferon-γ (IFN-γ) secreting CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cytotoxic cells. Recent studies have highlighted the role of TIM-3 as an important mediator of CD8<sup>+</sup> T cell exhaustion in the setting of chronic viral infections and cancer. In murine tumor models, antibody blockade of TIM-3 with anti-TIM-3 antibodies as monotherapy has no or minimal antitumor activity, suggesting that TIM-3 signaling exerts an accessory or amplifying effect in keeping immune responses in check. Using a combined bead and cell-based systemic evolution of ligands by exponential enrichment (SELEX) protocol, we have isolated nuclease-resistant oligonucleotide aptamer ligands that bind to cell-associated TIM-3 with high affinity and s"],"journal":["Molecular therapy : the journal of the American Society of Gene Therapy"],"pagination":["2280-2288"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5628791"],"repository":["biostudies-literature"],"pubmed_title":["A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice."],"pmcid":["PMC5628791"],"pubmed_authors":["Puplampu-Dove Y","Gefen T","Castro I","Patel S","Gilboa E","Muharemagic D"],"additional_accession":[]},"is_claimable":false,"name":"A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice.","description":"T cell immunoglobulin-3 (TIM-3) is a negative regulator of interferon-γ (IFN-γ) secreting CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cytotoxic cells. Recent studies have highlighted the role of TIM-3 as an important mediator of CD8<sup>+</sup> T cell exhaustion in the setting of chronic viral infections and cancer. In murine tumor models, antibody blockade of TIM-3 with anti-TIM-3 antibodies as monotherapy has no or minimal antitumor activity, suggesting that TIM-3 signaling exerts an accessory or amplifying effect in keeping immune responses in check. Using a combined bead and cell-based systemic evolution of ligands by exponential enrichment (SELEX) protocol, we have isolated nuclease-resistant oligonucleotide aptamer ligands that bind to cell-associated TIM-3 with high affinity and s","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Oct","modification":"2025-04-20T03:39:13.921Z","creation":"2019-03-26T23:57:55Z"},"accession":"S-EPMC5628791","cross_references":{"pubmed":["28800954"],"doi":["10.1016/j.ymthe.2017.06.023"]}}